Stockreport

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

Fate Therapeutics, Inc.  (FATE) 
Last fate therapeutics, inc. earnings: 3/2 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.fatetherapeutics.com/investor-relations
PDF Pre-treatment Sample of Patient’s Blood Showed Rapid and Potent Depletion of CD19+ B Cells in Ex Vivo Cytotoxicity Assay with FT819 Translational Data from FT819 Phas [Read more]